GKOS
NYSE Glaukos Corp$156.61 ↓ -1.95 (-1.23%) Trading Down from the previous close of $158.56
- YTD change
- +38.71%
- vs 20-day SMA
- -7.06%
- vs 200-day SMA
- +16.90%
Price ranges
Price & Performance
+53.55 (+51.00%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 18.3% away from all-time highs of $191.62
- GKOS is up 39% since the beginning of the year
- GKOS is up 93% over the past 12 months
- GKOS is down 13% over the past 1 month
- 8% of all GKOS investors are betting against GKOS
- Number of investors short GKOS has gone up 15% versus last month
GKOS reads neutral: price sits above one of the two key moving averages, short interest is rising month over month, the 12-month move is +95.1%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -3.04%
- vs 8-day SMA
- -1.19%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard A. Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.